期刊文献+

沙利度胺治疗复发性阿弗他溃疡的疗效系统评价 被引量:5

下载PDF
导出
摘要 复发性阿弗他溃疡(RAU)为最常见的口腔黏膜病,是指以周期性复发为特点的口腔黏膜局限性溃疡性损害。由于RAU发病因素很多,往往是各种因素的综合结果,加上全身因素在其中起到重要作用,因此相关的治疗方法很多,但目前仍无根治的方法^([1])。近年来,具有免疫调节与抗炎和抑制血管生成作用的沙利度胺用于治疗严重的RAU取得了一定的进展。本研究拟通过对中文2015年2月以前能够收集到的所有已发表的比较含沙利度胺[沙利度胺(+)]与不含沙利度胺[沙利度胺(-)]的方案治疗RAU的随机对照实验数据进行系统评价,评估反应停在治疗RAU中的疗效及安全性。
出处 《贵州医药》 CAS 2016年第1期65-68,共4页 Guizhou Medical Journal
基金 贵州省留学人员科技活动项目[黔人项目资助合同(2014-9)号] 贵州省自然科学基金[黔科合J字(2010)2165]
  • 相关文献

参考文献10

二级参考文献55

  • 1石晶,季旭东,陈谦明.应用沙利度胺治疗口腔黏膜病的进展[J].中华口腔医学杂志,2004,39(6):525-528. 被引量:3
  • 2陈谦明,周曾同.口腔黏膜病学[M].3版.北京:人民卫生出版,2008:101.
  • 3Revuz J,Guillaume JC,Janier M,et al.Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis[J].Arch Dermatol,1990,126:923-927.
  • 4Barrons RW. Treatment strategies for recurrent oral aphthous ulcers[J]. Am J Health Syst Rharm, 2001, 58(1):41-51.
  • 5Porter SR, Scully C, Flint S. Hematologic status in recurrent aphthous stomatitis compared with oral disease[J]. Oral Surg Oral Med Oral Pathol, 1988,66 :41-44.
  • 6Nolan A, McIntosh WB, Allam BF, et al. Recurrent aphthous ulceration: vi-tamin B1, B2 and B6 status and response to replacement therapy[J]. J Oral Pathol Med, 1991,20 (8) : 389- 391.
  • 7Figg WD, Raje S, Barzer KS, et al. Pharmeokineties of the thalidomide in an elderly Prostate cancer population[J]. Pharmsci. 1999,88 : 121-125.
  • 8Nasca MR, Tool e EA, Palicharla P, et al. Thalidomide increases human keratinocyte migration and proliferation[J]. J Invest Dermatol,1999, 113: 720-724.
  • 9Melchert M,List A.The thalidomide saga[J].Int J Biochem CellBiol,2007,39(7/8):1489-1499.
  • 10Wu JJ,Huang DB,Pang KR,et al.Thalidomide:dermatological in-dications,mechanisms of action and side-effects[J].Br J Derma-tol,2005,153(2):254-273.

共引文献43

同被引文献50

  • 1Belenguer-Guallar I,Jim6nez-Soriano Y, Claramunt-Lozano A. Treat ment of recurrent aphthous stomatitis.A literature review [J]. J Clin Exp Dent,2014,6(2):168-174.
  • 2Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalido- mide vs placebo in severe recurrent aphthous stomatitis [J]. Arch Dermatol, 1990,126 (7) :923 -927.
  • 3Jacobson JM,Greenspan J S, Spritzler J,et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunode- fieiency virus infection[J]. N Engl J Med,1997,336 (21):1487-1493.
  • 4Ramirez-Amador VA,Esquivel-Pedraza L,Ponee-de-Leon S,et al. T- halidomide as therapy for human immunodeficieney virus related oral uleers:a double blind placebo controlled clinical trial [J]. Clin Infect Dis, 1999,28 (4) :892-894.
  • 5Hello M,Barbarot S,Bastuji-Garin S,et al. Use of thalidomide for sev- er recurrent aphthous stomatitis: a muhicenter cohort analysis 0]. Medicine,2010,89(3): 176-182.
  • 6Bastuji-Garin S,Ochonisky S,Bouche P,et al. Incidence and risk fac- tors for thalidomide neuropathy: a prospective study of 135 dermato- logic patients [J]. J Invest Dermtol,2002,119(5):987-1020.
  • 7Tosi P,Zamagni E,Cellini C,et al. Neurological toxicity of long-term (>lyr) thalidomide therapy in patients with muhipie myaloma [J]. Eur J Haematol,2005,74 (3) :212-216.
  • 8Mileshkin L,Stark R,Day B,et al. Development of Neuropathy in Pa- tients With Myeloma Treated With Thalidomide: Patterns of Occur- rence and the Role of Electrophysiologic Monitoring [J]. J Clin On- col,2006,24(27):4507 -4514.
  • 9Hamuryudan V,Mat C,Saip S,et al. Thalidomide in the treatment of the mucocutaneous lesions of Behcet syndrome. A randomized, dou- ble-blind, placebo controlled trial Eli. Ann Intern Med,1998,128 (6): 443 -459.
  • 10Wazieres B,Gil H,Magy N,et al with low doses of thalidomide 07 Interne,1999,20 (7) :567-570.

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部